FDA approves Merck’s Keytruda in combination with chemotherapy for advanced lung cancer treatment
Merck’s cancer immunotherapy Keytruda (pembrolizumab) in combination with chemotherapy has been approved by the US Food and Drug Administration (FDA) as a first-line option for advanced lung cancer treatment in patients who didn’t take any medicines before for the disease.
The US Food and Drug Administration (FDA) has granted approval to Merck’s cancer immunotherapy, Keytruda (pembrolizumab), in combination with chemotherapy, as a first-line treatment option for patients with advanced lung cancer who have not previously been treated with other medicines. This approval marks a pivotal development in the battle against metastatic non-squamous non-small cell lung […]